Lantern Pharma Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Lantern Pharma Inc. (LTRN) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $78.35 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-30
- Lantern Pharma Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- Lantern Pharma Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $150.22K.
- Lantern Pharma Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- Lantern Pharma Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- Lantern Pharma Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $78.35K, a 77.53% decline from fiscal 2024.
- Lantern Pharma Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $348.62K, a 145.53% increase from fiscal 2023.
- Lantern Pharma Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $141.99K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $78.35K 10-K · filed 2026-03-30 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $150.22K derived: sum of 2 quarters · filed 2026-03-30 | $348.62K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $150.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $348.62K 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $198.41K 10-Q · filed 2025-08-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $93.18K derived: sum of 3 quarters · filed 2025-03-27 | $141.99K 10-K · filed 2025-03-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $93.18K derived: sum of 2 quarters · filed 2024-11-07 | $141.99K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $93.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $141.99K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $48.81K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |